Please ensure Javascript is enabled for purposes of website accessibility

Tag Archives: lupus

GlaxoSmithKline wins takeover bid for Human Genome

U.K. drug maker GlaxoSmithKline has secured its takeover of longtime partner Human Genome Sciences after agreeing to pay more, a move to expand GSK’s drug portfolio in crucial areas: biologic drugs and treatments for the hundreds of millions of people ...

Read More »

Report: GSK in deal talks with Human Genome

NEW YORK — GlaxoSmithKline PLC is reportedly talking this weekend with Human Genome Sciences Inc. about its $2.6 billion offer for the Rockville-based biotech company. British drug maker GlaxoSmithKline made its first bid for the biotech company in April and ...

Read More »

Human Genome adopts ‘poison pill’ measure

ROCKVILLE — Biotech drugmaker Human Genome Sciences Inc.’s board has adopted a “poison pill” shareholder rights plan to ward off unsolicited takeover bids, and it also has rejected a buyout offer worth nearly $2.6 billion from British pharmaceutical giant GlaxoSmithKline ...

Read More »

GlaxoSmithKline in takeover bid for Human Genome

LONDON — GlaxoSmithKline PLC has made an offer to take over Rockville-based drug maker Human Genome Sciences Inc. which values the company at nearly $2.6 billion. GlaxoSmithKline, which has profit-sharing agreements with HGS on three drugs but a minimal shareholding, ...

Read More »

Human Genome rejects GlaxoSmithKline’s $2.59B bid (access required)

The decision by Rockville-based biotech drugmaker Human Genome Sciences Inc. to reject an unsolicited $2.59 billion takeover bid Thursday may increase the eventual sale price of the company, analysts said. The question is by how much. “For the most part, ...

Read More »

Rockville-based Human Genome Sciences gets approval for new lupus drug

Benlysta, a drug to treat lupus, has received approval from European regulators to be marketed in Europe, the drug’s co-makers, Human Genome Sciences Inc. of Rockville, and GlaxoSmithKline, its London-based parent, announced. The European approval came two days after Benlysta, ...

Read More »

FDA scrutinizes benefit of long-awaited lupus drug

WASHINGTON — Federal health officials said Friday that the first new drug developed to treat lupus in decades relieves disease symptoms, but they questioned the significance of its benefits, which varied across difference patient groups. Human Genome Sciences is asking ...

Read More »